Companies

Covid-19: Shilpa Medicare ties up with Dr Reddy’s for Sputnik V

Our Bureau Bengaluru | Updated on May 17, 2021

Targeted production of dual vector vaccine for first 12 months is 50 million doses

Shilpa Medicare Limited, through its wholly-owned subsidiary Shilpa Biologicals Private Limited (SBPL), has entered into a three-year definitive agreement with Dr Reddy’s Laboratories Limited (DRL) for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing centre at Dharwad, Karnataka.

The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of component 1 and 50 million of component 2), from the date of start of commercial production, the company said in a regulatory filing to exchanges.

Sputnik Light

DRL has partnered with HVIRDIF for clinical development of the vaccine and has distribution rights in geographies including India. DRL will facilitate the transfer of the Sputnik technology to SBPL.

Apollo Hospitals begins pilot to administer SputnikV vaccines with Dr Reddy's Labs

“Under the agreement, SBPL will be responsible for manufacture of the vaccine, while DRL is responsible for distribution/marketing of the vaccine in its marketing territories. The companies are also exploring the option to manufacture Sputnik Light, a single-dose version of the vaccine in the near future,” company said.

Sputnik V: Second consignment of vaccines arrives in Hyderabad

The company views biologics as a strategic growth area and has made significant investments in setting up a high end, flexible biologics facility in Dharwad to cater to the requirements of the fast growing biologics field, which include the adenoviral, subunit and DNA vaccines, monoclonal antibodies and fusion proteins.

Published on May 17, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor